Cyprotex launches new Biosciences division

Cyprotex has launched a new Biosciences division, which will run alongside its ADME-Tox business.

The divisions will offer customers access to Cyprotex's 2D and 3D cell-based efficacy screening, which assesses the therapeutic or biological effects of new molecules.

The venture is the first time Cyprotex will promote its previous developments in high content screening, microelectrode array and cellular bionergetics.

"We are finding that customers are utilising our experience in existing specialist technologies for efficacy based screening activities," said chief executive officer Anthony Baxter.

"Introducing a Biosciences division is a natural progression from ADME-Tox, allowing us to further diversify our business without significant investment, and enabling us to expand into a new customer base," he added.

As of 0845 BST, Cyprotex was trading 2.8% lower at 52p.